CRBP — Corbus Pharmaceuticals Holdings, Inc.

Summary of Corbus Pharmaceuticals Q4 2020 Earnings Call

1. Key Financial Results and Metrics:

• Corbus reported a cash position of approximately $127 million as of March 15, 2021, expected to fund operations into Q1 2024.
• The company anticipates a reduced operational burn rate of around $10 million per quarter, down from $21 million in the previous quarter, due to cost-cutting measures including a workforce reduction.

2. Strategic Updates and Business Highlights:

• The company is focused on maximizing the value of its lead compound, lenabasum, particularly through the Phase 3 DETERMINE study for dermatomyositis, with topline results expected in Q2 2021.
• A protocol amendment moved the primary efficacy endpoint from week 52 to week 28, with all patients having completed the week 28 visit.
• Corbus is advancing its internal pipeline targeting the endocannabinoid system, with plans to initiate clinical studies for new drug candidates in 2022.
• The company is also exploring external partnerships to expand its pipeline beyond the endocannabinoid system.

3. Forward Guidance and Outlook:

• Corbus is optimistic about the upcoming data from the dermatomyositis study, which will inform future steps for lenabasum and its systemic sclerosis program.
• The company is committed to advancing its pipeline and expects to bring new compounds into clinical testing in 2022.

4. Bad News, Challenges, or Points of Concern:

• There are no new studies planned for lenabasum in cystic fibrosis, which may limit potential revenue streams from that indication.
• The company faces uncertainties regarding the regulatory landscape, particularly in light of the FDA's recent approval of Roche’s Actemra for systemic sclerosis, which was based on secondary analyses rather than primary endpoints. This raises questions about the FDA's willingness to approve drugs based on similar data.

5. Notable Q&A Insights:

• Discontinuation rates in the dermatomyositis study were reported at around 8%, which is lower than anticipated, with approximately 90% of eligible patients enrolling in the open-label extension.
• The company is analyzing the implications of Actemra's approval for lenabasum's potential in systemic sclerosis, particularly regarding forced vital capacity metrics observed in their studies.
• The timeline for further updates on the systemic sclerosis program will depend on the results from the dermatomyositis study, expected in the second half of 2021.

Overall, Corbus Pharmaceuticals is strategically positioning itself for growth while navigating challenges in clinical development and regulatory approval processes.